

# Resistance to *Mycobacterium tuberculosis* infection among household contacts of MDR TB patients

**Authors:** Davit Baliashvili,<sup>1</sup> Neel R. Gandhi,<sup>1</sup> Soyeon Kim,<sup>2</sup> Amita Gupta,<sup>3</sup> Gavin Churchyard,<sup>4</sup> Susan Swindells,<sup>5</sup> Anneke Hesselning,<sup>6</sup> Michael Hughes,<sup>2</sup> Sarita Shah<sup>7</sup> for ACTG 5300/IMPAACT I2003 PHOENix Feasibility study team

1. Emory Rollins School of Public Health, Atlanta, GA, USA 2. Harvard T.H. Chan School of Public Health, Boston, MA, USA 3. Johns Hopkins University, Department of Medicine, Baltimore, MD, USA 4. Aurum Institute, Parktown, South Africa 5. University of Nebraska Medical Center, Omaha, NE, USA 6. Desmond Tutu TB Centre – Stellenbosch University, Tygerberg, South Africa 7. Centers for Disease Control and Prevention, Atlanta, GA, USA

Scientific Research

E-Poster No. EP-04-131-31


THE 50<sup>TH</sup> UNION  
WORLD CONFERENCE  
ON LUNG HEALTH

## Background

- Household contacts (HHC) of TB patients are at high risk for TB infection and disease
- Yet 10–50% of HHC remain negative on tuberculin skin test (TST) or interferon gamma release assays (IGRA)<sup>1,2</sup>
- These individuals may be “resistant” to *Mycobacterium tuberculosis* (*Mtb*) infection
- Accurate measures of exposure are critical to determine whether individuals are resistant to *Mtb* infection
- An additional challenge is defining *Mtb* infection because TST and IGRA measure adaptive immune response, not infection itself
- We determined the proportion of HHC who may be “resistant” to *Mtb* infection despite high TB exposure**

## Design/Methods

- Cross-sectional study from 10/2015–4/2016, with follow-up at 1 year after enrollment
  - 16 sites in 8 countries: Botswana, Brazil, Haiti, India, Kenya, Peru, South Africa, and Thailand**
- Adult pulmonary Rif-resistant or MDR-TB index cases and their HHC
- HHC tested for *Mtb* infection:
  - Baseline TST and/or IGRA
  - Follow-up IGRA after 1-year for HHC with negative baseline IGRA (age≥5)
- Exposure variable:** 3-level variable (Figure 1) adapted from factors validated in published literature<sup>3,4</sup> including index case’s infectiousness, interaction with HHC, and age of HHC
- Definition of resistance to *Mtb* infection:**
  - Negative TST (0mm induration) and IGRA (<0.35 IU/ml) at baseline and negative IGRA after 1-year follow-up, if available; no active TB at baseline or after year.



## References

1. Simmons JD, Stein CM, Seshadri C, Campo M, Alter G, Fortune S, et al. Immunological mechanisms of human resistance to persistent *Mycobacterium tuberculosis* infection. *Nat Rev Immunol*. 2018;18(9):575-89.
2. Morrison J, Pai M, Hopewell PC. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. *Lancet Infect Dis*. 2008;8(6):359-68
3. Mandalakas AM, Kirchner HL, Lombard C, Walzl G, Grewal HM, Gie RP, et al. Well-quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection. *Int J Tuberc Lung Dis*. 2012;16(8):1033-9
4. Ma N, Zalwango S, Malone LL, Nsereko M, Wampande EM, Thiel BA, et al. Clinical and epidemiological characteristics of individuals resistant to *M. tuberculosis* infection in a longitudinal TB household contact study in Kampala, Uganda. *BMC Infect Dis*. 2014;14:352.

## Results

- Enrollment:** 1016 HHCs of 284 index cases (Figure 2). 305 (30%) HHCs <15 years old
- 306 (30%) HHCs** without TST and IGRA results available and without active TB were excluded from resistance definition.
- Resistance status defined for 710 HHC**, of whom **109 (15%)** were classified as resistant
  - Range: 0–50% across countries (Table 1)
  - Among HHCs with resistance defined, 328 were highly exposed, of whom **43 (13%)** were resistant




Table 1.		Country*							
Distribution of resisters by country		Botswana	Brazil	Haiti	India	Kenya	South Africa	Thailand	Total
Resistance status defined		37	9	48	174	8	404	30	710
Resistant	N	15	0	8	19	0	52	15	109
	%	40	0	17	11	0	13	50	15

\* Peru was excluded from the analysis because TST testing was not done

## Conclusions

- Even with restrictive classification (i.e., TST and IGRA negative, baseline and 1-year follow-up), a substantial proportion of HHC remain negative on tests for *Mtb* infection (15%)
- Resister phenotype occurs across diverse geographical settings
- Future directions may involve identifying genetic or immunologic factors potentially responsible for resistance to *Mtb* infection TB HHC randomized prevention

## Acknowledgements

We thank the study participants, study site staff, and entire protocol team. This work was supported in part by the NIH Fogarty International Center Global Infectious Diseases grant D43TW007124. Data was provided by the AIDS Clinical Trials Group (ACTG).

This research was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), Bethesda, MD, USA, under Award Numbers UM1AI068634, UM1AI068636 UM1AI106701, UM1A1068616, UM1AI068632, UM1AI068616 and UM1AI106716. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.